Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

GSK Scores Proteomics In Cellzome Acquisition

by Rick Mullin
May 21, 2012 | A version of this story appeared in Volume 90, Issue 21

GlaxoSmithKline has agreed to acquire the shares it does not currently own in Cell­zome to access the latter’s proteomics platform for drug development. GSK currently owns just less than 20% of Cellzome through previous drug development collaborations. It will pay about $99 million for the rest of the company. Cellzome’s proteomic mass spectrometry and screening technology has been deployed in early-stage research on immune-inflammation therapies at GSK. The deal marks GSK’s third acquisition of a platform technology in the past five years. In 2007, the drug firm acquired Domantis, a developer of next-generation antibody therapies, and Praecis, a specialist in chemical synthesis and screening technologies. GSK and Cellzome shareholders plan to create a spin-off company retaining the rights to Cellzome assets that GSK does not plan to pursue.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.